Sign In
Buy SPRO
$2.80
-0.0300 (-1.06%)
At Close: Jun 03, 2026
Earnings Preview: Spero Therapeutics, Inc. (SPRO) Q1 Earnings Expected to Decline
07:02pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Spero Therapeutics to Present Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases
12:05pm, Thursday, 21'st Apr 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced two oral presentations and four poster presentations at the 32nd European Congress of Cl
Spero Therapeutics to Present Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases
08:05am, Thursday, 21'st Apr 2022
CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced two oral presentations and four poster presentations at the 32nd European Congress of Clin
Spero Therapeutics Tebipenem Pivoxil Hydrobromide Phase 3 Data Published in The New England Journal of Medicine
09:31pm, Wednesday, 06'th Apr 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced publication in The New England Journal of Medicine (NEJM) of the results from the Phase
Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q4 2021 Results - Earnings Call Transcript
10:48pm, Thursday, 31'st Mar 2022
Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q4 2021 Results - Earnings Call Transcript
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Lags Revenue Estimates
09:55pm, Thursday, 31'st Mar 2022 Zacks Investment Research
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -12.50% and 5.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s
Spero Therapeutics Announces Fourth Quarter and Full Year 2021 Operating Results and Provides Business Update
08:05pm, Thursday, 31'st Mar 2022 GlobeNewswire Inc.
Provides update on ongoing FDA review of Tebipenem HBr NDA
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Lags Revenue Estimates
07:33pm, Thursday, 31'st Mar 2022
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -12.50% and 5.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
12:14pm, Thursday, 31'st Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Amylyx Says FDA Committee Casts Negative Vote On ALS Drug
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
Is a Surprise Coming for Spero Therapeutics (SPRO) This Earnings Season?
02:39pm, Tuesday, 29'th Mar 2022 Zacks Investment Research
Spero Therapeutics (SPRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Surprise Coming for Spero Therapeutics (SPRO) This Earnings Season?
12:02pm, Tuesday, 29'th Mar 2022
Spero Therapeutics (SPRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 31, 2022
12:05pm, Thursday, 17'th Mar 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that it will host a conference call and live audio webcast on Thursday, March 31, 2022,
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 31, 2022
08:05am, Thursday, 17'th Mar 2022
CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that it will host a conference call and live audio webcast on Thursday, March 31, 2022, a
Spero Therapeutics antibiotic SPR206 shows promise in phase 1 trial
02:06pm, Wednesday, 16'th Feb 2022 Seeking Alpha
Spero Therapeutics (SPRO) reported positive results from a phase 1 trial of its antibiotic SPR206 to treat serious multi-drug resistant ((MDR)) gram-negative infections in the…
Spero Therapeutics Sees Positive Topline Results for Antibiotic Trial
01:17pm, Wednesday, 16'th Feb 2022 MarketWatch
By Chris Wack Spero Therapeutics Inc. said it saw positive topline findings from its Phase 1 bronchoalveolar lavage clinical trial of SPR206, an…
